Clinical effects of arbekacin on MRSA infections after oral and maxillofacial surgery

K. Onizawa, K. Uchiyama, H. Iwabuchi, K. Tsunoda, Y. Okada, S. Asanami

Research output: Contribution to journalArticle

Abstract

Clinical and bacteriological effects of arbekacin (ABK) were studied in a total of 9 patients with methicillin-resistant Staphylococcus aureus (MRSA) infections after oral and maxillofacial surgery. ABK was administered by intravenous drip infusion at a close of 100mg twice a day for 7 to 14 days, and imipenem/cilastatin was administered to 3 patients, minocyclin to 1 patient, and lomefloxacin to 1 patient, simultaneously. The clinical efficacy rate of ABK was 77.8%. As to the bacteriological effect. MRSA was eradicated in 4 (44.4%) out of 9 patients. As to the administration methods, the clinical efficiencies were 80.0% in 5 monotherapy cases and 83.3% in 4 combined therapy cases. In conclusion, this study suggested that ABK is useful for treatment of MRSA infections after oral and maxillofacial surgery.

Original languageEnglish
Pages (from-to)10-14
Number of pages5
JournalOral Therapeutics and Pharmacology
Volume16
Issue number1
Publication statusPublished - 1997 Jan 1

Keywords

  • After oral and maxillofacial surgery
  • Arbekacin sulfate
  • MRSA infections

ASJC Scopus subject areas

  • Dentistry(all)
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical effects of arbekacin on MRSA infections after oral and maxillofacial surgery'. Together they form a unique fingerprint.

  • Cite this

    Onizawa, K., Uchiyama, K., Iwabuchi, H., Tsunoda, K., Okada, Y., & Asanami, S. (1997). Clinical effects of arbekacin on MRSA infections after oral and maxillofacial surgery. Oral Therapeutics and Pharmacology, 16(1), 10-14.